Notable Reporting: Is Xencor Inc’s Fuel For Real? The Stock Just Increased Again

October 14, 2016October 14, 2016Adrian Mccoy

The stock of Xencor Inc (NASDAQ:XNCR) is a huge mover today! About 15,011 shares traded hands. Xencor Inc (NASDAQ:XNCR) has risen 70.96% since March 11, 2016 and is uptrending. It has outperformed by 65.50% the S&P500.
The move comes after 9 months positive chart setup for the $866.48 million company. It was reported on Oct, 14 by Barchart.com. We have $34.43 PT which if reached, will make NASDAQ:XNCR worth $545.88M more.

Xencor Inc (NASDAQ:XNCR) Ratings Coverage

Out of 5 analysts covering Xencor (NASDAQ:XNCR), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Xencor has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, September 17 by Leerink Swann. On Wednesday, August 5 the stock rating was maintained by MLV with “Buy”. Canaccord Genuity initiated Xencor Inc (NASDAQ:XNCR) rating on Tuesday, December 22. Canaccord Genuity has “Buy” rating and $20 price target. The firm has “Overweight” rating given on Tuesday, October 4 by Piper Jaffray. The firm has “Hold” rating given on Friday, September 4 by Zacks. The stock of Xencor Inc (NASDAQ:XNCR) has “Outperform” rating given on Tuesday, March 8 by Leerink Swann. The firm earned “Hold” rating on Saturday, August 8 by Zacks.

According to Zacks Investment Research, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.”

Insitutional Activity: The institutional sentiment increased to 1.64 in Q2 2016. Its up 0.40, from 1.24 in 2016Q1. The ratio is positive, as 10 funds sold all Xencor Inc shares owned while 23 reduced positions. 13 funds bought stakes while 41 increased positions. They now own 27.63 million shares or 4.30% less from 28.87 million shares in 2016Q1.
Teacher Retirement Systems Of Texas accumulated 0% or 4,484 shares. Pnc Fin Services Group Inc has 0% invested in the company for 66,126 shares. Franklin last reported 796,801 shares in the company. Reilly Advsrs Limited Co accumulated 0% or 200 shares. Sphinx Trading L P holds 128,018 shares or 4.84% of its portfolio. Deere Communications, a Illinois-based fund reported 29,388 shares. The New York-based Qvt Fincl Limited Partnership has invested 0.51% in Xencor Inc (NASDAQ:XNCR). Proshare Advsr Lc owns 34,269 shares or 0.01% of their US portfolio. Metropolitan Life Insurance Ny accumulated 0% or 24,320 shares. Equitec Specialists Ltd Limited Liability Company holds 5,489 shares or 0.02% of its portfolio. Thompson Davis & accumulated 0% or 125 shares. Blackrock Japan has 0% invested in the company for 1,057 shares. Manufacturers Life Insur The accumulated 0% or 22,735 shares. Northern accumulated 0% or 388,049 shares. State Street Corp last reported 0% of its portfolio in the stock.

Insider Transactions: Since May 24, 2016, the stock had 0 insider purchases, and 18 insider sales for $8.24 million net activity. Dahiyat Bassil I sold $596,523 worth of Xencor Inc (NASDAQ:XNCR) on Tuesday, May 24. Another trade for 40,000 shares valued at $1.03M was sold by STAFFORD JOHN S III. Baracchini Edgardo Jr had sold 4,528 shares worth $90,560 on Wednesday, August 3. Shares for $77,074 were sold by CARTER BRUCE L A on Thursday, August 11. $20,123 worth of shares were sold by Foster Paul A on Tuesday, June 28. Shares for $354,065 were sold by Desjarlais John R on Tuesday, August 23.

More important recent Xencor Inc (NASDAQ:XNCR) news were published by: Fool.com which released: “This Caused Xencor Inc.’s Stock to Jump 11.6% in August” on September 10, 2016, also Fool.com published article titled: “Why Xencor Inc’s Shares Are Skyrocketing Today”, Prnewswire.com published: “Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195” on September 15, 2016. More interesting news about Xencor Inc (NASDAQ:XNCR) was released by: Prnewswire.com and their article: “Xencor Doses First Patient in Lead Immuno-Oncology Bispecific Program …” with publication date: September 12, 2016.

XNCR Company Profile

Xencor, Inc., incorporated on June 8, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company’s segment is related to the development of pharmaceutical products. The Firm uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The Company’s clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. The Company’s oncology product candidates are in preclinical stage, which include XmAb14045 for the treatment of acute myeloid leukemia (AML) and XmAb13676 for B-cell malignancy. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 (MOR208), an antibody drug candidate, and XmAb13551, a bispecific CD38 x CD3 preclinical candidate.